Michael Robert Ballinger

Array ( [id] => 18108036 [patent_doc_number] => 20230000916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => ANTI-CD3 SCFV AND CYTOKINE PRODUCING ARTIFICIAL ANTIGEN PRESENTING CELLS [patent_app_type] => utility [patent_app_number] => 17/778734 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837953 [patent_doc_number] => 20210145965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHOD OF USING CHECKPOINT KINASE INHIBITOR THERAPY TO MODULATE ANTI-TUMORAL RESPONSE AGAINST CANCER AND SENSITIZE GLIOMAS TO IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/951638 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075871 [patent_doc_number] => 20220401483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE [patent_app_type] => utility [patent_app_number] => 17/774821 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -99 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806172 [patent_doc_number] => 20210128725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => CYTOTOXIC LIPID PARTICLES TARGETED TO TUMOR-ASSOCIATED MYELOID CELLS (TAMCS) AND SYNERGIZED WITH RADIATION THERAPY FOR TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/089563 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806066 [patent_doc_number] => 20210128619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/089594 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885713 [patent_doc_number] => 20210171908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => ALLOGENEIC T-CELLS AND METHODS FOR PRODUCTION THEREOF [patent_app_type] => utility [patent_app_number] => 17/088759 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17088759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16779376 [patent_doc_number] => 20210116454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE [patent_app_type] => utility [patent_app_number] => 17/075594 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595354 [patent_doc_number] => 20220144927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => HUMANIZED ANTIBODY AND METHOD FOR USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/430704 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032487 [patent_doc_number] => 20240082302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => Compositions and Methods for Targeting CD13 and TIM-3 with CAR T Cells to Treat Acute Myeloid Leukemia [patent_app_type] => utility [patent_app_number] => 17/767831 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733436 [patent_doc_number] => 11802159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) [patent_app_type] => utility [patent_app_number] => 17/037203 [patent_app_country] => US [patent_app_date] => 2020-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 36 [patent_no_of_words] => 39775 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17037203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718570 [patent_doc_number] => 20210085717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 17/030258 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977192 [patent_doc_number] => 12344653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Antigen binding molecules for small cell lung cancer [patent_app_type] => utility [patent_app_number] => 17/025991 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 34 [patent_no_of_words] => 50081 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075925 [patent_doc_number] => 20220401537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => CHIMERIC RECEPTOR PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/760747 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541000 [patent_doc_number] => 20200407413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/019059 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541001 [patent_doc_number] => 20200407414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/019091 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671307 [patent_doc_number] => 20210060070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => ADOPTIVE CELL THERAPY AND METHODS OF DOSING THEREOF [patent_app_type] => utility [patent_app_number] => 17/011636 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806064 [patent_doc_number] => 20210128617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS [patent_app_type] => utility [patent_app_number] => 17/005227 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612232 [patent_doc_number] => 20210030885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/934745 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671331 [patent_doc_number] => 20210060094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER [patent_app_type] => utility [patent_app_number] => 16/932048 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621905 [patent_doc_number] => 20210040558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => METHOD TO ISOLATE TCR GENES [patent_app_type] => utility [patent_app_number] => 16/927661 [patent_app_country] => US [patent_app_date] => 2020-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927661 [rel_patent_id] =>[rel_patent_doc_number] =>)